


32. Kuti JL, Moss KM, Nicolau DP, Knauf FR. Empiric treatment of multidrug-resistant *Burkholderia cepacia* lung exacerbation in a patient with cystic fibrosis:


52. Ellis JM, **Kuti JL**, Nicolau DP. Use of Monte Carlo simulation to assess the pharmacodynamics of β-lactams against *Pseudomonas aeruginosa* infections in


ABSTRACTS


8a. **Kuti JL**, Florea NR, Nightingale CH, Nicolau DP. Pharmacodynamics of Meropenem and Imipenem Against Enterobacteriaceae and *Pseudomonas*


31a. Sykes RB, Sahani J, Ellis JM, Kuti JL. Retrospective comparison of lipid amphotericin B complex (ABLC) and liposomal amphotericin B (L-AMB) in the pediatric population (Abstract 113). 2005 Spring Practice and Research Forum of
the American College of Clinical Pharmacy, Myrtle Beach, SC, April 10-13, 2005.


33a. Sun HK, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials for the empiric treatment of nosocomial pneumonia: a report from the OPTAMA program. 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 2-5, 2005.

34a. Ludwig E, Maglio D, Konkoly-Thege M, Kuti J, Nicolau D. Pharmacodynamic comparison of intravenous antimicrobials against Pseudomonas aeruginosa in Hungarian hospitals - A report from the OPTAMA Program. 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 2-5, 2005.


53a. Kim A, Sutherland C, Kuti J, Nicolau D. Optimal piperacillin/tazobactam dosing against Pseudomonas aeruginosa: prolonged or continuous infusion?
(Abstract). 17th European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany, March 31 to April 3, 2007.


